Table 4.
Univariate and multivariate analyses of various prognostic parameters in patients with breast cancer Cox-regression analysis
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Patients, number | P-value | Regression coefficient (SE) | P-value | Relative risk | 95% confidence interval | |
| Transducin (β)-like 1 X-linked receptor 1 | <0.001 | 1.642 (0.301) | 0.012 | 2.590 | 1.237, 5.422 | |
| Low expression | 103 | |||||
| High expression | 111 | |||||
| Ki67 | <0.001 | 1.518 (0.283) | 0.034 | 2.126 | 1.058, 4.271 | |
| Low expression | 111 | |||||
| High expression | 103 | |||||
| Clinical stage | ||||||
| I | 21 | |||||
| II | 107 | <0.001 | 0.804 (0.158) | 0.007 | 1.593 | 1.135, 2.237 |
| III | 66 | |||||
| IV | 20 | |||||
| Pathological differentiation | 0.001 | 0.873 (0.258) | 0.026 | 1.809 | 1.074, 3.050 | |
| Well-differentiated | 8 | |||||
| Moderately differentiated | 154 | |||||
| Poorly differentiated | 52 | |||||
Transducin (β)-like 1 X-linked receptor 1 (TBLR1) protein expression level in breast cancer significantly correlated with patient survival time (P <0.001). The correlation coefficient was -0.512 indicating that higher levels of TBLR1 expression correlate with shorter survival time. For 5-year survival: low expression, 86.4% (79.1% to 93.7%); high expression, 51.9% (42.1% to 61.7%).